You are here
Gilead wins reversal of US$2.54b hepatitis C drug patent verdict
A US federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record US$2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.
The verdict had been the largest ever in a US
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org